alectinib
Sponsor NUVL · listed as NUVL
READOUT
Phase 2;Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2026-10-31
As disclosedOct 31, 2026
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT03178552
PhasePHASE2;PHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorHoffmann-La Roche
Listed asNUVL
Condition(s)Non-Small Cell Lung Cancer
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More NUVL catalysts